Navigation Links
Alvespimycin in Medical News
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
...osium). Kosan has expanded this Phase 1 trial to include the combination of alvespimycin plus trastuzumab and paclitaxel (Taxol(R)). In the first quarter 2008, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy in patients with HER2-positive metastatic breast cancer who ...Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...Alvespimycin in Medical Technology
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
...sion on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania. About......ients with HER2-positive metastatic breast cancer. alvespimycin has demonstrated the potential to disrupt the acti... to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previou...ium demonstrated encouraging antitumor activity of alvespimycin in combination with trastuzumab (Herceptin(R)). ...
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone......trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
...ting in June Phase I Trial Expanding to Include alvespimycin Plus Trastuzumab Plus Pa.... We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establ...his year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date v...
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
...combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
... initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety pro......apolis, IN, in a poster, titled, "Phase 1 Trial of alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 ...leadership in the Hsp90 inhibitor area." Phase 1 alvespimycin Results alvespimycin is a second-generation Hsp90 inhibitor that has de...
Alvespimycin in Biological Technology
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
... demonstrated potential activity. -- Kosan will withdraw Hsp90 inhibitor alvespimycin from development in order to commit resources to the development of ta...tabine(R)) and/or Herceptin(R). Kosan plans to discontinue development of alvespimycin in lieu of development of tanespimycin. The process of ending current alves......trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...
Kosan Announces Third Quarter 2007 Financial Results
...e presentation of updated positive Phase 1 data on alvespimycin in HER2-positive metastatic breast cancer; Phase 1...a Phase 2 monotherapy trial of our Hsp90 inhibitor alvespimycin in newly-diagnosed patients with HER2-positive met...cal trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated antitumor activity and tolerabili...Kosan to Reacquire Epothilone Program From Roche
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...Kosan Biosciences to Host Research & Development Day on October 31, 2007
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhib...Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...Other TagsOther Contents
HongTightenedoutburstpitfallsOmbudsmanCircumstancesArticPracticedFoeticideHoaxprobedPlagueddenoteEVT
(Date:6/19/2013)... no-strings sexual encounters are increasingly common on college ... others to "hook up"? A new study by ... and Preventive Medicine, published online by the ... certain factors and behaviors associated with sexual hookups, ... the potential for negative emotional and physical health ...
(Date:6/19/2013)... that block the body,s system for repairing damage to ... As unlikely as it may seem, those compounds are ... cancers driven by a mutation in BRCA, a gene ... carries the mutation. The compounds, termed PARP inhibitors, are ... edition of Chemical & Engineering News . C&EN ...
(Date:6/19/2013)... Center and colleagues at Louisiana State University have developed ... immediate therapy. It relies on understanding the genetic interaction ... better predict a prostate cancer,s aggressiveness to avoid unnecessary ... the online journal PLOS ONE in April. ... 20 percent of all cancers and 9 percent of ...
(Date:6/19/2013)... Hills, CA (PRWEB) June 19, 2013 ... Hills, permits some patients to quit using drugs while ... and Adi Jaffe, the founders of Alternatives, believe that ... Bottom” before they enter treatment and that this approach ... 22 million people in the United States need treatment ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Many ... deem it medically necessary, according to a ... Child Health Journal. The results of this research ... more than a decade – that trying-to-conceive women ... maintaining a healthy body weight. Fairhaven Health is ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4[0] Why are some college students more likely to 'hook up'?[0] Renewed hope in a once-abandoned cancer drug class[0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers[0] Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment[0] Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies
(Date:6/19/2013)... 2013 A decade-long JDRF-funded study led by ... Mnchen, Germany, is providing a deeper understanding of ... developing type 1 diabetes (T1D), highlighting the importance ... disease. The study, "Seroconversion to Multiple Islet Autoantibodies ... was published today in The Journal of ...
(Date:6/19/2013)... NEW YORK , June 19, 2013 New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of scientific, ... to announce the launch of a new open access ... of GeoResJ , Elsevier,s earth and planetary science ... The journal aims to provide a forum for rapid ... field. The journal will be co-edited by six Executive ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |